Singapore, Aug 27, 2010: Lotus Pharmaceuticals, a developer, manufacturer and seller of medicine and drugs in China, has started R-Bambuterol clinical trial phase I, as per schedule, and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.

The studies are co-monitored by the company and Beijing Zenith International Medical Science and Technology Development, a mid-size full-service clinical research organization, and carried out in Peking University Third Hospital, a top-ranked AAA hospital recognized as a base adherence to the principles of good clinical practices (GCPs).

R-Bambuterol Hydrochloride Tablets showed significant efficacy and less toxicity in preclinical trials as an anti-asthma drug than Bambuterol currently available in the market.

If it reaches the market, R-Bambuterol Hydrochloride Tablets would address the Chinese asthma and chronic obstructive pulmonary disease (COPD) market led by AstraZeneca with a 26 percent share in 2009, according to IMS.